Vis enkel innførsel

dc.contributor.authorVeneti, Lamprini
dc.contributor.authorSeppälä, Elina Marjukka
dc.contributor.authorStorm, Margrethe Larsdatter
dc.contributor.authorValcarcel Salamanca, Beatriz
dc.contributor.authorBuanes, Eirik Alnes
dc.contributor.authorAasand, Nina Therese
dc.contributor.authorNaseer, Mohammed Umaer
dc.contributor.authorBragstad, Karoline
dc.contributor.authorHungnes, Olav
dc.contributor.authorBøås, Håkon
dc.contributor.authorKvåle, Reidar
dc.contributor.authorSamareh Golestani, Karan
dc.contributor.authorFeruglio, Siri Laura
dc.contributor.authorVold, Line
dc.contributor.authorNygård, Karin Maria
dc.contributor.authorWhittaker, Robert Neil
dc.date.accessioned2022-01-18T13:05:34Z
dc.date.available2022-01-18T13:05:34Z
dc.date.created2021-12-15T13:53:48Z
dc.date.issued2021
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11250/2837952
dc.description.abstractIntroduction Since their emergence, SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.351 have spread worldwide. We estimated the risk of hospitalisation and admission to an intensive care unit (ICU) for infections with B.1.1.7 and B.1.351 in Norway, compared to infections with non-VOC. Materials and methods Using linked individual-level data from national registries, we conducted a cohort study on laboratory-confirmed cases of SARS-CoV-2 in Norway diagnosed between 28 December 2020 and 2 May 2021. Variants were identified based on whole genome sequencing, partial sequencing by Sanger sequencing or PCR screening for selected targets. The outcome was hospitalisation or ICU admission. We calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable binomial regression to examine the association between SARS-CoV-2 variants B.1.1.7 and B.1.351 with i) hospital admission and ii) ICU admission compared to non-VOC. Results We included 23,169 cases of B.1.1.7, 548 B.1.351 and 4,584 non-VOC. Overall, 1,017 cases were hospitalised (3.6%) and 206 admitted to ICU (0.7%). B.1.1.7 was associated with a 1.9-fold increased risk of hospitalisation (aRR 95%CI 1.6–2.3) and a 1.8-fold increased risk of ICU admission (aRR 95%CI 1.2–2.8) compared to non-VOC. Among hospitalised cases, no difference was found in the risk of ICU admission between B.1.1.7 and non-VOC. B.1.351 was associated with a 2.4-fold increased risk of hospitalisation (aRR 95%CI 1.7–3.3) and a 2.7-fold increased risk of ICU admission (aRR 95%CI 1.2–6.5) compared to non-VOC. Discussion Our findings add to the growing evidence of a higher risk of severe disease among persons infected with B.1.1.7 or B.1.351. This highlights the importance of prevention and control measures to reduce transmission of these VOC in society, particularly ongoing vaccination programmes, and preparedness plans for hospital surge capacity.en_US
dc.language.isoengen_US
dc.publisherPLOSen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIncreased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020-May 2021en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.source.articlenumbere0258513en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1371/journal.pone.0258513
dc.identifier.cristin1968961
dc.source.journalPLOS ONEen_US
dc.identifier.citationPLOS ONE. 2021, 16 (10), e0258513.en_US
dc.source.volume16en_US
dc.source.issue10en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal